
Project Leader of the Pancreas Bioengineering unit @SanRaffaeleDRI @SanRaffaeleMI. Immediate past-Chair @IPITA_YIC
Milan, MI
Joined August 2011
- Tweets235
- Following423
- Followers230
- Likes374
Pinned Tweet
🚨🚨🚨don’t miss this fantastic opportunity! Submit your application @IPITA_YIC
🚨OPPORTUNITY!
Working on β-cell replacement therapies? Trainee or <5 yrs of an appointment?
Join IPITA's Young Investigator Committee!
Be a member of a global community shaping the future of β-cell replacement.
Email a CV (2p) and letter of interest (1p) to [email protected]
Antonio Citro retweeted
Looking forward to chairing the #ADA2025 session "Innovating Stem Cell Manufacturing and Engraftment Strategies for Cell Replacement Therapy" with many excellent speakers! Join us at 3:45p in room W196 BC.
Antonio Citro retweeted
The 2025 World Congress of the International Pancreas and Islet Transplant Association (IPITA) opening ceremony at the amazing Teatro Verdi in Pisa
#IPITA2025
#IslandTransplantation
#diabetes
#diabetesawareness
#NothingAboutUsWithoutUs
#DiabeteItalia
#IDFEurope – at Pisa, Tuscany
Antonio Citro retweeted
We had a wonderful time at the Young Investigator Committee social event to kick off an exciting conference at IPITA 2025 in Pisa, Italy! The future of pancreas and islet transplantation looks bright #IPITA2025 #IPITA_YIC
Get ready for an unforgettable experience — IPITA 2025 is landing in Pisa! 🇮🇹 The countdown has officially begun… are you in? 😉 #IPITA2025
🎯 IPITA 2025, Pisa, Italy- June 15–18, 2025
🚀 Leading the way in islet & pancreas transplant innovation
Be part of the science shaping the future of Type 1 Diabetes treatment
🌍 Join experts
📈 Share your work
🤝 Connect & collaborate
🧭 See you in Pisa!
#IPITA2025
🚀 Exciting News! 🚀
Our manuscript "Bioengineering of a Human iPSC-derived Vascularized Endocrine Pancreas for Type 1 Diabetes" is officially online in Cell Reports Medicine! 📰🎉 #BT1D #betacellreplacmet #tissueengineering
cell.com/cell-reports-medici…
Don’t miss the opportunity to join to IPITA YIC! 7 days left! 💪
🚨OPPORTUNITY - 7 DAYS LEFT!
Working on β-cell replacement therapies? Trainee or <5 yrs of an appointment?
Join IPITA's Young Investigator Committee!
Be part of a global community shaping the future of β-cell replacement.
CV (2p) and letter of interest (1p) to [email protected]
Antonio Citro retweeted
🚨OPPORTUNITY - 7 DAYS LEFT!
Working on β-cell replacement therapies? Trainee or <5 yrs of an appointment?
Join IPITA's Young Investigator Committee!
Be part of a global community shaping the future of β-cell replacement.
CV (2p) and letter of interest (1p) to [email protected]
Antonio Citro retweeted
🌍💙Today, we stand united to support millions living with diabetes. Diabetes is more than numbers; it's resilience, strength, and hope.
IPITA commits to advance research, raise awareness, and keep striving for a diabetes-free world.
#WorldDiabetesDay #EndDiabetes #HopeForACure
Antonio Citro retweeted
🚨SCHOLARSHIP!
Trainee with MD, PhD or MD/PhD working on pancreas/islet transplant research?
Derek Gray Distinguished Traveling Scholarship.
Visit institutions around the world to learn from leaders in the field ✈🌍!
DEADLINE Jan 17, 2025.
Apply here👇🏼
shorturl.at/WosaA
Antonio Citro retweeted
🚨OPPORTUNITY!
Working on β-cell replacement therapies? Trainee or <5 yrs of appointment?
Join IPITA's Young Investigator Committee!
Be part of a global community shaping the future of β-cell replacement.
CV (2p) and LOI (1p) to [email protected]
DEADLINE is NOV 30 2024!🏃🏼🏃♀️
Antonio Citro retweeted
Breakthrough Update: Today, Vertex announced that they are beginning their Phase 3, or pivotal trial for VX-880, a stem cell-derived islet therapy. A pivotal trial gathers the data required for an FDA submission. This therapy is for people with type 1 diabetes (T1D) and hypoglycemia unawareness and severe hypoglycemic episodes.
This is a HUGE first for the #T1D community as it is the first time a scalable cure for some people with T1D is entering this phase.
Breakthrough T1D and the T1D Fund are incredibly proud to have supported this work in cell therapies—a top priority for our organization. We want to congratulate our partners at Vertex and thank all the patients who have participated in clinical trials. Your courage and commitment are inspiring.
Learn more here: bit.ly/48DuLTd
Antonio Citro retweeted
🚨8 MONTHS from the biggest conference on BETA-CELL replacement in the world! Ready to meet the LEADERS IN THE FIELD and learn about the GROUNDBREAKING SCIENCE getting us closer to a cure for diabetes? What are you waiting?
Join us in Pisa, Italy!
SAVE THE DATE->June 15-18, 2025
🚨paper alert🚨 happy to have contribute to explore the potential of porcine islets as a viable alternative to human donor islets for beta cell replacement in Type 1 Diabetes (T1D) @PiemontiL @spartelli @BreakthroughT1D
This Post is from an account that no longer exists. Learn more
Antonio Citro retweeted
From the September Issue of @annsurgoncol: Establishment of a Transplantation Model of PDAC-Derived Liver Metastases rdcu.be/dSZxA
@Citro_Lab
@DrSabha
@SyedAAhmad5
September Issue: Establishment of a Transplantation Model of PDAC-Derived #LiverMetastases @Citro_Lab
rdcu.be/dSZxA
@DrSabha
@SyedAAhmad5
Antonio Citro retweeted
September Issue: Establishment of a Transplantation Model of PDAC-Derived #LiverMetastases @Citro_Lab
rdcu.be/dSZxA
@DrSabha
@SyedAAhmad5
Antonio Citro retweeted
The advances in cell therapy and achieving immune tolerance are laying the foundations for a cure for Type 1 diabetes in the future.
This is a new and exceptional review of the field
nature.com/articles/s41574-0…
@GrattoniLab @NatureRevEndo
Antonio Citro retweeted
Our comprehensive review of #LongCovid has just been published
nature.com/articles/s41579-0…
Phenomenal work by @ahandvanish @LisaAMcCorkell @juliamv
@NatureRevMicro
Honored to be part of a collaborative review in @NatRevEndo alongside an amazing group, exploring advances in cell therapies for Type 1 Diabetes. #CellTherapy #T1D #RegenerativeMedicine #BreakthroughT1D.
Read more here: nature.com/articles/s41574-0…



























